PMID- 37204453
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Linking)
VI  - 34
IP  - 8
DP  - 2023 Aug
TI  - Association of C-peptide level with bone mineral density in type 2 diabetes 
      mellitus.
PG  - 1465-1476
LID - 10.1007/s00198-023-06785-9 [doi]
AB  - This study revealed that there was no significant linear relationship between 
      fasting C-peptide (FCP) level and bone mineral density (BMD) or fracture risk in 
      type 2 diabetes mellitus (T2DM) patients. However, in the FCP </= 1.14 ng/ml group, 
      FCP is positively correlated with whole body (WB), lumbar spine (LS), and femoral 
      neck (FN) BMD and negatively correlated with fracture risk. PURPOSE: To explore 
      the relationship between C-peptide and BMD and fracture risk in T2DM patients. 
      METHODS: 530 T2DM patients were enrolled and divided into three groups by FCP 
      tertiles, and the clinical data were collected. BMD was measured by dual-energy 
      X-ray absorptiometry (DXA). The 10-year probability of major osteoporotic 
      fractures (MOFs) and hip fractures (HFs) was evaluated by adjusted fracture risk 
      assessment tool (FRAX). RESULTS: In the FCP </= 1.14 ng/ml group, FCP level was 
      positively correlated with WB, LS, and FN BMD, while FCP was negatively 
      correlated with fracture risk and osteoporotic fracture history. However, FCP was 
      not correlated with BMD and fracture risk and osteoporotic fracture history in 
      the 1.14 < FCP </= 1.73 ng/ml and FCP > 1.73 ng/ml groups. The study has shown that 
      FCP was an independent factor influencing BMD and fracture risk in the 
      FCP </= 1.14 ng/ml group. CONCLUSIONS: There is no significant linear relationship 
      between FCP level and BMD or fracture risk in T2DM patients. In the 
      FCP </= 1.14 ng/ml group, FCP is positively correlated with WB, LS, and FN BMD and 
      negatively correlated with fracture risk, and FCP is an independent influencing 
      factor of BMD and fracture risk. The findings suggest that FCP may predict the 
      risk of osteoporosis or fracture in some T2DM patients, which has a certain 
      clinical value.
CI  - (c) 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis 
      Foundation.
FAU - Yang, Hong
AU  - Yang H
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
FAU - Bai, Jia
AU  - Bai J
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
FAU - Li, Lingling
AU  - Li L
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
FAU - Yang, Ying
AU  - Yang Y
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
FAU - Zhang, Yangyang
AU  - Zhang Y
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
FAU - Lv, Haihong
AU  - Lv H
AUID- ORCID: 0000-0003-3059-6549
AD  - Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, 
      Gansu, China. haihonglv@126.com.
FAU - Fu, Songbo
AU  - Fu S
AD  - Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, 
      Gansu, China.
LA  - eng
GR  - No. 20JR10FA667/Clinical Medical Research Center of Endocrine Diseases of Gansu 
      Province/
GR  - No. 2021JSCX0011/Science and Technology Planning project of Lanzhou Chengguan 
      District/
GR  - No. 21JR1RA080/Natural Science Foundation of Gansu Province/
PT  - Journal Article
DEP - 20230519
PL  - England
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation 
      between the European Foundation for Osteoporosis and the National Osteoporosis 
      Foundation of the USA
JID - 9100105
RN  - 0 (C-Peptide)
SB  - IM
MH  - Humans
MH  - Bone Density
MH  - *Osteoporotic Fractures/complications
MH  - *Diabetes Mellitus, Type 2/complications
MH  - C-Peptide
MH  - *Osteoporosis/complications
MH  - Absorptiometry, Photon
MH  - Risk Factors
MH  - Risk Assessment
OTO - NOTNLM
OT  - Bone mineral density
OT  - C-peptide
OT  - Fracture risk
OT  - Type 2 diabetes mellitus
EDAT- 2023/05/19 13:05
MHDA- 2023/07/31 06:42
CRDT- 2023/05/19 11:05
PHST- 2022/11/22 00:00 [received]
PHST- 2023/05/01 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/05/19 13:05 [pubmed]
PHST- 2023/05/19 11:05 [entrez]
AID - 10.1007/s00198-023-06785-9 [pii]
AID - 10.1007/s00198-023-06785-9 [doi]
PST - ppublish
SO  - Osteoporos Int. 2023 Aug;34(8):1465-1476. doi: 10.1007/s00198-023-06785-9. Epub 
      2023 May 19.